MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Operating Cash Flow 2011-2026 | AMPH
Annual Operating Cash Flow Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 156 M | 213 M | 184 M | 89.2 M | 98 M | 57.3 M | 41.8 M | 38.2 M | 39.2 M | 38.6 M | 10.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 213 M | 10.7 M | 87.8 M |
Quarterly Operating Cash Flow Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 35.1 M | - | - | - | 55.3 M | - | - | - | 40.4 M | - | - | 53.6 M | 50.8 M | - | - | 55 M | 22.8 M | - | 40.4 M | 31.6 M | 1.48 M | - | 36.1 M | 48.1 M | -3.61 M | - | 28.7 M | 12.9 M | 8.36 M | - | 29.4 M | 27 M | 22.4 M | - | 24.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 55.3 M | -3.61 M | 31 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
181 M | $ 4.81 | 2.02 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
-131 M | $ 3.37 | 3.45 % | $ 339 M |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.2 | 4.75 % | $ 5.27 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 334.86 | -1.34 % | $ 43.9 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-82.5 M | $ 7.36 | -15.79 % | $ 72.8 M | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 2.08 | 1.22 % | $ 432 M | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.86 | 4.76 % | $ 27.9 M | Israel |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Forte Biosciences
FBRX
|
-50.9 M | $ 31.11 | -4.04 % | $ 403 M | USA |
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
-504 M | $ 29.11 | 0.8 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
1.33 B | $ 29.26 | 0.67 % | $ 18.8 B |  Danmark |
 |
GT Biopharma
GTBP
|
-12.9 M | $ 0.38 | -1.83 % | $ 2.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
348 M | $ 29.22 | -0.24 % | $ 1.68 B | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 99.83 | 1.44 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 7.64 | -1.18 % | $ 69 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
InflaRx N.V.
IFRX
|
-39.9 M | $ 1.21 | 6.14 % | $ 152 M | Germany |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
68 M | $ 1.54 | -1.23 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
|
Immatics N.V.
IMTX
|
-81.8 M | $ 10.97 | 0.18 % | $ 690 M | Germany |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.19 | 1.07 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 24.26 | -3.31 % | $ 3.09 B | USA |
 |
Incyte Corporation
INCY
|
1.41 B | $ 97.7 | 0.01 % | $ 19.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-58.5 M | $ 1.66 | 1.57 % | $ 235 M | France |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.48 | -0.34 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |